The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
Bhavatarini Vangamudi(Vanderbilt University Medical Center), Jannik N. Andersen(Tango Therapeutics (United States)), Harshad S. Mahadeshwar(The University of Texas MD Anderson Cancer Center), Parantu K. Shah(Ono Pharmaceutical (United States)), Trang N. Tieu(The University of Texas MD Anderson Cancer Center), Carlo Toniatti(The University of Texas MD Anderson Cancer Center), Shikhar Sharma(Pfizer (United States)), Alessia Petrocchi(The University of Texas MD Anderson Cancer Center), Giulio Draetta(The University of Texas MD Anderson Cancer Center), Mike Peoples(The University of Texas MD Anderson Cancer Center), Dafydd R. Owen(Pfizer (United States)), Joseph R. Marszalek(The University of Texas MD Anderson Cancer Center), Wylie S. Palmer(Nurix (United States)), Thomas A. Paul(Pfizer (United States)), Timothy P. Heffernan(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(Wellcome Sanger Institute), Philip Jones(The University of Texas MD Anderson Cancer Center), Lisa Nottebaum(La Jolla Alcohol Research), Maria Kost‐Alimova(Broad Institute), Yanai Zhan(The University of Texas MD Anderson Cancer Center), Dominique Verhelle(Pfizer (United States)), Alexei Protopopov, Xi Shi(Broad Institute), Elisabetta Leo(Ipsen (United Kingdom))
Cited by 275
Related Papers
The cancer genome
|Nature|2009|3.5k
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
|Nucleic Acids Research|2010|2.3k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k